Associated tags: Patient, CNS, Public, Infection, Hepatology, Republic, Biotechnology, Health, Pharmaceutical industry, Vaccine, HBV, HBsAg
Locations: UNITED STATES, CHINA
Retrieved on:
Wednesday, January 3, 2024
Drug discovery,
GSK plc,
Biotechnology,
Health,
Therapy,
GSK,
HIV,
Publication,
ViiV Healthcare,
Infection,
Medicine,
Pharmaceutical industry Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.
Key Points:
- Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.
- "I am thrilled to reunite with Brian as our Chief Scientific Officer," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.
- Prior to joining Brii Bio, Dr. Johns served as the Chief Scientific Officer at HemoShear Therapeutics, Inc., where he led his team to novel targets and platforms in various disease areas.
- "I am excited to join Brii Biosciences and contribute to the development of transformative therapies against infectious diseases," said Dr. Brian A. Johns.
Retrieved on:
Monday, November 13, 2023
Hepatology,
Grade 2,
FAS,
Plasma,
AASLD,
Biotechnology,
Vaccination,
Patient,
HBV,
EOT,
Enzyme inhibitor,
Week,
Liver,
Health,
Liver cancer,
CHB,
MD,
Trial of the century,
PPS,
Seroconversion,
Hepatitis,
Pharmaceutical industry,
Vaccine,
HBsAg,
Boston DURHAM, N.C. and BEIJING, Nov. 13, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today shared three posters at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston, MA, two of which were accepted as late-breakers providing new data from two Phase 2 assets, BRII-179 (VBI-2601) and BRII-835 (VIR-2218), within the chronic hepatitis B (CHB) clinical program.
Key Points:
- "We are pleased to share these data at The Liver Meeting that demonstrate the versatility of our HBV portfolio and critical insight in our search for a cure for HBV," said David Margolis, MD, Chief Medical Officer of Brii Bio.
- "The important connection between HBsAg loss and antibody response provides a clear direction in further improving the functional cure rate and identifying patients who will most likely respond to curative treatments.
- Highlights include:
The PK characteristics of BRII-835 in patients with chronic HBV infection are generally similar to those in healthy volunteers.
- In addition, Vir Biotechnology, Inc. ("Vir") is also investigating VIR-2218 and/or VIR-3434 for the treatment of HBV/HDV co-infection.
Partnership,
Prevalence,
Public,
Biotechnology,
Hepatitis B virus,
VBI,
HBsAg,
Patient,
VBI Vaccines,
Population density,
Ageing,
Health,
Vaccine,
HBV,
PROTECT,
Pharmaceutical industry,
European BEIJING and DURHAM, N.C., July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into license agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), expanding the companies' collaboration in the hepatitis B virus (HBV) field.
Key Points:
- The newly formed license agreements with VBI signify a substantial expansion in the fight against HBV infection.
- In the first agreement, Brii Bio's exclusive license for BRII-179 (VBI-2601) is extended to worldwide markets, further establishing its leadership position in pursuing HBV functional cure.
- VBI is also eligible to receive additional payments based on achievement of regulatory and commercial milestones, as well as royalties.
- "By exploring the combination cure strategies across our portfolio, we aim to produce the most durable curative treatment in the broadest populations of HBV patients.
DURHAM, N.C. and BEIJING, April 27, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") Report, outlining the Company's progress and performance toward long-term growth and success in key ESG areas. The report is available on the Company's website under the "About Us" section.
Key Points:
- DURHAM, N.C. and BEIJING, April 27, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") Report, outlining the Company's progress and performance toward long-term growth and success in key ESG areas.
- The report is available on the Company's website under the "
Retrieved on:
Wednesday, April 21, 2021
Other Health,
Research,
General Health,
Pharmaceutical,
Oncology,
Infectious diseases,
Clinical trials,
Science,
Biotechnology,
FDA,
Other Science,
Health,
Medical specialties,
Clinical medicine,
Infectious diseases,
Hepadnaviridae,
Hepatitis B,
Hepatitis,
HBV,
BRII-835 (VIR-2218),
BRII-179 (VBI-2601),
Brii Biosciences,
Vir Biotechnology,
VBI Vaccines Inc.,
BRII-835 (VIR-2218),
BRII-179 (VBI-2601),
BRII BIOSCIENCES,
VIR BIOTECHNOLOGY,
VBI VACCINES INC. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
Key Points:
- This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
- Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
- Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
- Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.
Retrieved on:
Wednesday, April 21, 2021
Health,
Infectious diseases,
Clinical trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Medical specialties,
Hepadnaviridae,
HBV,
Hepatitis B,
Infectious diseases,
Clinical medicine,
BRII-835 (VIR-2218),
BRII-179 (VBI-2601),
Brii Biosciences,
Vir Biotechnology,
VBI Vaccines Inc.,
BRII-835 (VIR-2218),
BRII-179 (VBI-2601),
BRII BIOSCIENCES,
VIR BIOTECHNOLOGY,
VBI VACCINES INC. Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
Key Points:
- Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
- Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
- VIR-2218 is the first asset in the Company\xe2\x80\x99s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
- Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.
Venture capital,
Biotechnology,
Pharmaceutical,
Finance,
Health,
Infectious diseases,
Professional services,
Clinical trials,
Medical terminology,
Actuarial science,
Disease,
Brii Biosciences,
Invesco Developing Markets Fund,
GIC,
Lake Bleu Capital Brii Biosciences (Brii Bio), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155 million.
Key Points:
- Brii Biosciences (Brii Bio), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155 million.
- Proceeds from the financing will be used to advance Brii Bios broad infectious diseases pipeline as well as the companys CNS program.
- Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system.
- Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and CNS diseases.
Retrieved on:
Wednesday, November 18, 2020
Research,
Infectious diseases,
FDA,
Clinical trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Medical specialties,
Clinical medicine,
Medicine,
Virology,
Hepadnaviridae,
Hepatitis B,
Vaccine,
Hepatitis,
Hepatitis B,
VBI Vaccines Inc.,
Brii Biosciences VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.
Key Points:
- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.
- This study was designed to assess the ability of VBI-2601 (BRII-179) to induce or restore antibody and T cell responses against HBV.
- Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
- VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
Retrieved on:
Tuesday, October 22, 2019
Under the terms of the agreement, Brii Biosciences will obtain a license to develop, manufacture, and commercialize the portfolio in greater China, which includes Taiwan, Hong Kong, Macau and the People's Republic of China.
Key Points:
- Under the terms of the agreement, Brii Biosciences will obtain a license to develop, manufacture, and commercialize the portfolio in greater China, which includes Taiwan, Hong Kong, Macau and the People's Republic of China.
- Brii Biosciences will make an upfront payment, as well as success-based development, regulatory and commercial milestone payments, and share in the costs of a global development program.
- Qpex Biopharma will also receive tiered royalties on sales in the Brii Bio territory.
- The company is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and other illnesses.
